

The efficacy of biologic-based immunotherapies relies on their ability to induce apoptosis and cell death through the recruitment and activation of immune effector cells. The HiBiT Target Cell Killing (TCK) Bioassays include a target cancer cell engineered to express a HiBiT fusion protein that remains intracellular until cell lysis. Upon cell death and membrane disruption, HiBiT is released into the media where it is stable for >3 days. Substrate addition allows for HiBiT to bind with high affinity to its LgBiT counterpart to form the functional NanoBiT luciferase. The resulting luminescent signal is proportional to the number of dead cells in the culture and is specific to target cell death.

Durability

 HiBiT protein is detectable as early as 8hrs post-transfection and is stable for >3 days

Dynamic Signal-to-Noise Ratio

• Robust signal with as little as 2,000 cells or 500 cells in a 384 well format

Suitable For Screening

Allows for multiple different cell lines and antigen
KO's to be screened to determine the optimal target cell for your biologic

Synergize With Qualified Effector Cells

 Human PBMCs, CD8+ T cells and Macrophages qualified for ADCC, TDCC and ADCP activity respectively with our TCK cells are available



HiBiT Target Cell Killing Bioassays:

A Validated Assay To Measure Target & Antigen-Specific Cell Death



ViaScript and TCK technologies combine for a powerful platform to test biologic MoAs: HepG2 cells were transfected with ViaScript[™] (HiBiT) TCK technology followed by a 24hr TDCC bioassay using CD8+ T cells and the indicated biologic. A) GPC3 x CD3, B) Ertumaxomab (EpCam x CD3) and C) Catumaxomab (EpCAM x CD3)

Join the Academic Access Program for exclusive perks! Contact our Tailored R&D Solutions to generate a stable TCK line! Take advantage of our **Thaw & Use Format** for stable TCK lines for reliable and consistent assays

PROMEGA CORPORATION • 2800 WOODS HOLLOW ROAD • MADISON, WI 53711-5399 USA • TELEPHONE 608-274-4330 www.promega.com • ©2024 PROMEGA CORPORATION • ALL RIGHTS RESERVED • PRICES AND SPECIFICATIONS SUBJECT TO CHANGE WITHOUT PRIOR NOTICE • CREATED 09/24 – GFN207